LAVA Therapeutics NV
LVTXDelisted Nov 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001840748
LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.
13F holders, Q2 2025
Institutional positions in LAVA Therapeutics NV as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −1 vs. Q1 2025
- Shares held
- 8.05M
- +6.94K (+0.1%) vs. Q1 2025
- Total value
- $10.6M
- +$411.4K (+4.0%) vs. Q1 2025
- New holders
- 3
- 4 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 21 | $16.1M |
| Q2 2025 | 19 | $10.6M |
| Q1 2025 | 20 | $10.2M |
| Q4 2024 | 22 | $6.15M |
| Q3 2024 | 21 | $5.99M |
| Q2 2024 | 19 | $6.77M |
| Q1 2024 | 20 | $12.5M |
| Q4 2023 | 14 | $9.22M |
| Q3 2023 | 14 | $8.47M |
| Q2 2023 | 15 | $11.7M |
| Q1 2023 | 19 | $11.2M |
| Q4 2022 | 20 | $26.3M |
| Q3 2022 | 13 | $34.1M |
| Q2 2022 | 17 | $22.8M |
| Q1 2022 | 18 | $35.2M |
| Q4 2021 | 20 | $44.3M |
| Q3 2021 | 19 | $48.6M |
| Q2 2021 | 18 | $95.5M |
| Q1 2021 | 24 | $139.1M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 300 | $396 | 0.00% | 00.0% | Unchanged |
| Jones Financial Companies LLLP | 400 | $528 | 0.00% | +400 | New |
| TSFG, LLC | 400 | $1.00K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 11,600 | $15.3K | 0.00% | −200−1.7% | Reduced |
| Geode Capital Management, LLC | 14,170 | $18.7K | 0.00% | −1,994−12.3% | Reduced |
| Two Sigma Securities, LLC | 14,236 | $18.8K | 0.00% | +14,236 | New |
| UBS Group AG | 16,380 | $21.6K | 0.00% | −515−3.0% | Reduced |
| Rangeley Capital, LLC | 27,073 | $35.7K | 0.05% | +27,073 | New |
| Lepercq De Neuflize Asset Management LLC | 31,000 | $40.9K | 0.04% | +8,000+34.8% | Added |
| Two Sigma Investments, LP | 34,412 | $45.4K | 0.00% | −23,303−40.4% | Reduced |
| BNP Paribas Arbitrage, SA | 46,900 | $61.9K | 0.00% | +1,600+3.5% | Added |
| Citadel Advisors LLC | 51,804 | $68.4K | 0.00% | +46,781+931.3% | Added |
| The PNC Financial Services Group, Inc. | 65,000 | $85.8K | 0.00% | 00.0% | Unchanged |
| Pathway Financial Advisors LLC | 102,500 | $135.3K | 0.02% | 00.0% | Unchanged |
| Bruce & Co., Inc. | 521,874 | $688.9K | 0.22% | 00.0% | Unchanged |
| Merck & Co., Inc. | 1,149,345 | $1.52M | 0.70% | 00.0% | Unchanged |
| Sanofi | 1,919,455 | $2.53M | 1.44% | 00.0% | Unchanged |
| BML Capital Management, LLC | 1,970,610 | $2.60M | 1.99% | +10,000+0.5% | Added |
| Redmile Group, LLC | 2,074,372 | $2.74M | 0.29% | 00.0% | Unchanged |
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −48,420−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −24,307−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1,300−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −1,110−100.0% | Sold out |